As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
IBC is a rare, aggressive breast cancer with higher rates in younger women and those of African descent, requiring a ...
Investment analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Nuvalent in a report released on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback